ArticleHaematologica2025

Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.

Shuangyou Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.